Abstract
Background Off-label drug use (OLU) reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many health care systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based health care, treatment ought to be reimbursed if there is sufficient clinical evidence for treatment benefit independently of patient factors not related to the treatment indication. However, little is known about the reality of OLU reimbursement and its association with the underlying clinical evidence. Here we aim to investigate the relationship of reimbursement decisions with the underlying clinical evidence.
Methods/Design We extract patient characteristics and details on treatment and reimbursement of cancer drugs from over 3000 patients treated in three Swiss hospitals. We systematically search for clinical trial evidence on benefits associated with OLU in the most common indications. We will describe the prevalence of OLU in Switzerland and its reimbursement in cancer care, and use multivariable logistic regression techniques to investigate the association of approval/rejection of a reimbursement requests to the evidence on treatment effects and to further factors, including type of drug, molecular predictive markers and the health insurer.
Discussion Our study will provide a systematic overview and assessment of OLU and its reimbursement reality in Switzerland. We may provide a better understanding of the access to cancer care that is regulated by health insurers and we hope to identify factors that determine the level of evidence-based cancer care in a highly diverse Western health care system.
- Off-label use
- evidence-based health care
- reimbursement
- cancer therapy
Competing Interest Statement
BK declares consultant activities for Roche and Siemens, research grants from Roche/AbbVie, travel support from Riemser, AbbVie and Amgen. UN declares consultation or advisory role for Roche, Astra, Gilead, Celgene, and honoraria (congress participations) from Amgen, Novartis, Takeda, Roche. All other authors declare that they have no competing interests.
Funding Statement
This project was fully funded by the Swiss Cancer League with a research grant for post-doc salaries and expendables (Grant KFS-4262-08.2017). The funding body had no influence on the design of the study, the collection, analysis and interpretation of data, and on writing the manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Not applicable.
Abbreviations
- CEIT
- Comparative Effectiveness of Innovative Treatments
- EMA
- European Medicines Agency
- FDA
- Food and drugs association
- FOPH (Swiss)
- Federal Office of Public Health
- HER2
- Human epidermal growth factor receptor 2
- OLU
- Off-label Use
- OS
- Overall survival
- PFS
- Progression free survival
- PICO
- Population, intervention, control, outcome
- RCT
- Randomized controlled study
- SM
- Swissmedic
- SR
- Systematic review